In this episode of Dose of Discovery, hosts Søren and AJ speak to physician-scientist Stanley Crooke, CEO of the nonprofit n-Lorem Foundation, about how antisense oligonucleotide (ASO) technology has evolved into a revolutionary therapeutic modality.
Their conversation explores Stan's expansive career journey, from his early days building cancer programs at Bristol Labs and SmithKline to his bold decision to launch Ionis in 1989 when the industry doubted ASO technology.
Stan discusses the emotional rollercoaster of biotech drug development, the inefficiencies of traditional small molecule discovery, and what led him to establish the n-Lorem Foundation.
He shares how the regulatory frontiers of treating nano-rare genetic conditions “for free, for life” are changing rapidly and why innovations like patient-derived stem cells are driving drug development forward, one patient at a time.
In this episode:
About the guest
Physician-scientist Stanley Crooke, founder of Ionis Pharmaceuticals, and founder, chairman, and CEO of the n-Lorem Foundation. Widely regarded as a pioneer of antisense medicine, he helped lead the development and commercialization of the first approved ASO therapies. Today, his work through nonprofit organization the n-Lorem Foundation focuses on creating and providing bespoke ASO treatments to patients suffering from nano-rare genetic conditions (affecting fewer than 30 people worldwide) for free, for life. Crooke studied pharmacy at Butler University and went on to earn his MD and PhD at Baylor College of Medicine.
https://www.nlorem.org/wp-content/uploads/2023/08/Stanley-T.-Crooke-M.D.-Ph.D.-Bio.pdf
Dose of Discovery is cohosted by Søren Hough and Ayokunmi Ajetunmobi (AJ) and produced by Suze Cooper.
LINKS:
Kinds of KANDness: Battling nano-rare disease with oligos by Søren Hough
Therapeutic oligos for no profit: A discussion with n-Lorem by Søren Hough
‘For free, for life’: n-Lorem carves path for bespoke treatment by Søren Hough
Deep brain penetration by oligos enables Alzheimer’s, Parkinson’s treatment by Søren Hough (ASO treatment for neurodegeneration)
Oligo-based therapies lead charge against prion disease by Nnenna Ohaka (Getting ASOs into the brain)
Phosphorothioate antisense oligonucleotide induced innate immune activation is attenuated by tryptophan oxidation products (Making safe ASOs by Crooke and colleagues)
Establishing a commercial solution for extremely rare genetic diseases (Commercializing ASOs for rare disease by Crooke & Lo)
Read more at Bioxconomy, sign up to our newsletter, and don’t forget to check out our upcoming events.
You can find a fully annotated transcript of the episode here.
","author_name":"Søren Hough"}